Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of  CFTR  Genotype | Zendy

Clancy J P | Zendy; Johnson S G | Zendy; Yee S W | Zendy; McDonagh E M | Zendy; Caudle K E | Zendy; Klein T E | Zendy; Cannavo M | Zendy; Giacomini K M | Zendy

Premium

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype

Author(s) -

Clancy J P,

Johnson S G,

Yee S W,

McDonagh E M,

Caudle K E,

Klein T E,

Cannavo M,

Giacomini K M

Publication year - 2014

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2014.54

Subject(s) - ivacaftor , cystic fibrosis transmembrane conductance regulator , cystic fibrosis , context (archaeology) , pharmacogenetics , medicine , genotype , pharmacology , gene , genetics , biology , paleontology

Cystic fibrosis (CF) is a life‐shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D‐CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results. Clinical Pharmacology & Therapeutics (2014); 95 6, 592–597. doi: 10.1038/clpt.2014.54

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research